Pressure Biosciences (PBIO) versus The Competition Head-To-Head Survey

Pressure Biosciences (OTCMKTS: PBIO) is one of 25 publicly-traded companies in the “Analytical instruments” industry, but how does it weigh in compared to its rivals? We will compare Pressure Biosciences to related businesses based on the strength of its earnings, analyst recommendations, profitability, risk, institutional ownership, valuation and dividends.


This table compares Pressure Biosciences and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pressure Biosciences -403.86% N/A -392.92%
Pressure Biosciences Competitors -212.02% -25.29% -11.33%

Insider and Institutional Ownership

62.4% of shares of all “Analytical instruments” companies are owned by institutional investors. 15.9% of Pressure Biosciences shares are owned by company insiders. Comparatively, 13.5% of shares of all “Analytical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Pressure Biosciences has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Pressure Biosciences’ rivals have a beta of 1.45, meaning that their average share price is 45% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Pressure Biosciences and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pressure Biosciences 0 0 0 0 N/A
Pressure Biosciences Competitors 183 917 1284 65 2.50

As a group, “Analytical instruments” companies have a potential upside of 0.70%. Given Pressure Biosciences’ rivals higher possible upside, analysts plainly believe Pressure Biosciences has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Pressure Biosciences and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Pressure Biosciences $2.46 million -$9.70 million -0.16
Pressure Biosciences Competitors $1.14 billion $146.92 million 11.84

Pressure Biosciences’ rivals have higher revenue and earnings than Pressure Biosciences. Pressure Biosciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


Pressure Biosciences rivals beat Pressure Biosciences on 8 of the 10 factors compared.

About Pressure Biosciences

Pressure BioSciences, Inc. develops pressure cycling technology (PCT) solutions. Its PCT technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations, including Barocycler 2320EXT, Barozyme-HT48, Barocycler NEP3229, HUB440, HUB880, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as PCT MicroTubes, PCT-MicroCaps, PCT-Micro-Pestle, PULSE Tubes, and BaroFlex 8-well Processing Strips, as well as application specific kits. Pressure BioSciences, Inc. serves researchers at academic laboratories; government agencies; and biotechnology, pharmaceutical, and other life sciences institutions in the United States, Europe, and Asia. Pressure BioSciences, Inc. has a collaboration with NutraFuels, Inc. for the development of water-soluble Nanoemulsion-based nutraceuticals. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was founded in 1978 and is based in South Easton, Massachusetts.

Receive News & Ratings for Pressure Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pressure Biosciences and related companies with's FREE daily email newsletter.